Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

被引：0
|
作者：
J Feliu
J Barriuso
机构：
[1] Medical Oncology Service,
[2] Hospital La Paz/Autónoma University School of Medicine,undefined
[3] IdiPAZ,undefined
[4] RETIC,undefined
[5] P° de la Castellana,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：226 / 226
相关论文
共 50 条
  • [41] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    [J]. ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [42] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [45] Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
    Omrcen, T.
    Katic, A.
    Tomic, S.
    Eterovic, D.
    Vrdoljak, E.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [46] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    [J]. JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [47] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [48] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [49] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [50] Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
    Zhao, G.
    Gao, P.
    Yang, K. H.
    Tian, J. H.
    Ma, B.
    [J]. COLORECTAL DISEASE, 2010, 12 (07) : 615 - 623
12345